Mutant ARID1A: igniting cancer immunotherapy

Bujamin H Vokshi; Eneda Toska

doi:10.1016/j.it.2024.07.003

Mutant ARID1A: igniting cancer immunotherapy

Trends Immunol. 2024 Aug;45(8):565-567. doi: 10.1016/j.it.2024.07.003. Epub 2024 Jul 26.

Authors

Bujamin H Vokshi¹, Eneda Toska²

Affiliations

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA. Electronic address: etoska1@jhmi.edu.

PMID: 39068111
DOI: 10.1016/j.it.2024.07.003

Abstract

Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS-STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.

Publication types

Review

MeSH terms

Animals
DNA-Binding Proteins* / genetics
DNA-Binding Proteins* / immunology
DNA-Binding Proteins* / metabolism
Humans
Immunotherapy* / methods
Membrane Proteins / genetics
Membrane Proteins / immunology
Membrane Proteins / metabolism
Mutation
Neoplasms* / immunology
Neoplasms* / therapy
Signal Transduction
Transcription Factors* / genetics
Transcription Factors* / immunology
Transcription Factors* / metabolism

Substances

Transcription Factors
DNA-Binding Proteins
ARID1A protein, human
Membrane Proteins